NEWS
Making it easy for our investors to stay current with our portfolio companies and their industries.
January 12, 2025
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
November 21, 2024
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
November 18, 2024
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
November 13, 2024
Southeast urologist deploys AI tool, boosting cancer identification by 25%
November 13, 2024
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update